TIGIT can be targeted by selective compounds such as the anti-TIGIT humanized mAb vibostolimab, resulting in effective antitumor responses against both solid tumors and hematological neoplasms [100]. This evidence concerns the gene TIGIT and hematopoietic and lymphoid system neoplasm.